Impact of Lysine Acetylation Mutations on the Structure of Full-Length Tau Fibrils
- PMID: 40599054
- DOI: 10.1021/acschemneuro.5c00149
Impact of Lysine Acetylation Mutations on the Structure of Full-Length Tau Fibrils
Abstract
The tau protein aggregates into amyloid fibrils in Alzheimer's disease and other neurodegenerative diseases. In these tauopathies, tau is decorated with posttranslational modifications, including phosphorylation and acetylation, suggesting that these modifications may cause tau to aggregate into specific pathological structures. Here, we investigate how pseudoacetylation of three lysine residues, K311Q, K321Q, and K369Q, affects the fibrilization and fibril structure of full-length four-repeat tau. These acetyl mimics are in addition to four phospho-mimetic glutamate mutations at the PHF1 epitope (4E tau). The joint mutant 4E3Q tau formed well-ordered amyloid fibrils without anionic cofactors. The 4E3Q tau fibrils lack twists, preventing structure determination by cryoelectron microscopy and necessitating characterization by solid-state NMR. 13C and 15N chemical shifts indicate that pseudoacetylation caused the protein to adopt a distinct fold from the parent 4E tau fibrils: the rigid core contains β-strands between R2 and R4 repeats and near the end of the C-terminal domain. Importantly, the C-terminal half of the R3 repeat containing the K321Q mutation is disordered, in qualitative contrast with 4E tau. Chemical shifts indicate that these structural changes likely result from the disruption of salt bridges between lysine and aspartate residues. 4E3Q tau contains an immobilized R2, which differs from that of AD tau. These results provide insights into the impact of acetylation on tau fibrilization and fibril structure and suggest that acetylation of these three lysine residues in AD may occur after the formation of the paired-helical filament structure.
Keywords: Alzheimer’s disease; cryoEM; posttranslational modification; protein aggregation; salt bridge; solid-state NMR.
Similar articles
-
Milligram-scale assembly and NMR fingerprint of tau fibrils adopting the Alzheimer's disease fold.J Biol Chem. 2024 Jun;300(6):107326. doi: 10.1016/j.jbc.2024.107326. Epub 2024 Apr 26. J Biol Chem. 2024. PMID: 38679331 Free PMC article.
-
Binding Sites of a PET Ligand in Tau Fibrils with the Alzheimer's Disease Fold from 19F and 13C Solid-State NMR.Biochemistry. 2025 Apr 1;64(7):1624-1635. doi: 10.1021/acs.biochem.5c00016. Epub 2025 Mar 11. Biochemistry. 2025. PMID: 40068133 Free PMC article.
-
Structures of ΔD421 Truncated Tau Fibrils.J Mol Biol. 2025 May 15;437(10):169051. doi: 10.1016/j.jmb.2025.169051. Epub 2025 Feb 26. J Mol Biol. 2025. PMID: 40021051
-
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2. Cochrane Database Syst Rev. 2017. PMID: 28328043 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources